Description
Anti-IRTA4 Antibody, Non-Fucosylated (BioBet-874ZP) is a human monoclonal IgG antibody against IRTA4. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
B-cell malignancies
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IRTA4 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
FCRL2
Full Name
Fc receptor-like 2
Background
This gene encodes a member of the immunoglobulin receptor superfamily and is one of several Fc receptor-like glycoproteins clustered on the long arm of chromosome 1. The encoded protein has four extracellular C2-type immunoglobulin domains, a transmembrane domain and a cytoplasmic domain that contains one immunoreceptor-tyrosine activation motif and two immunoreceptor-tyrosine inhibitory motifs. This protein may be a prognostic marker for chronic lymphocytic leukemia. Alternatively spliced transcript variants have been described, but their biological validity has not been determined.
Alternative Names
FCRL2; Fc receptor-like 2; FCRH2; IFGP4; IRTA4; SPAP1; CD307b; SPAP1A; SPAP1B; SPAP1C; Fc receptor-like protein 2; IFGP family protein 4; fc receptor homolog 2; immunoglobulin superfamily Fc receptor, gp42; SH2 domain containing phosphatase anchor protein 1; immune receptor translocation-associated protein 4; immunoglobulin receptor translocation-associated protein 4
Gene ID
79368
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with FCRL2 include Spastic Paraplegia 62, Autosomal Recessive.
Function
May have an regulatory role in normal and neoplastic B cell development.
Post-translational modifications
1.Isoform 2 is N- and O-glycosylated, and phosphorylated 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn343, Asn355, Asn365, Asn204, and Asn234
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-874ZP
Description
The monoclonal antibody that specifically bind to IRTA-4 with high affinity can be used for treating various B cell malignancies, including non-Hodgkin's lymphoma.
Antibody Indication
B-cell malignancies
